Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Qari, Mohamad H ^a   Wali, Yasser ^b   Albagshi, Muneer H ^c   Alshahrani, Mohammad ^d   Alzahrani, Azzah ^d   Alhijji, Ibrahim A ^e   Almomen, Abdulkareem ^f   Aljefri, Abdullah ^g   Al Saeed, Hussain H ^h   Abdullah, Shaker ⁱ   Al Rustumani, Ahmad ^j   Mahour, Khoutir ^k   Mousa, Shaker A ^l  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b SULTAN QABOOS UNIVERSITY   (Oman)

^c Maternity and Children Hospital   (Saudi Arabia)

^d Prince Sultan Military Medical City   (Saudi Arabia)

^e HAMAD MEDICAL CORPORATION   (Qatar)

^f KING SAUD UNIVERSITY   (Saudi Arabia)

^g KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^h QATIF CENTRAL HOSPITAL   (Saudi Arabia)

ⁱ KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^j Medical Education Department   (United Arab Emirates)

^k Hôpital de Jour   (France)

^l ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

more..

Author keywords

Anemia; Arabian Gulf; Chelation; Iron chelation therapy; Iron overload; Thalassemia management; Transfusion

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FLUDARABINE; HEPCIDIN; HYDROXYUREA; IRON CHELATING AGENT; METHOTREXATE; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN; VITAMIN D;

ADENOHYPOPHYSIS; AGRANULOCYTOSIS; ANEMIA; APPLICATION SITE IRRITATION; ARTHROPATHY; BETA THALASSEMIA; BLOOD CELL COUNT; BLOOD COMPONENT; BLOOD TRANSFUSION; BONE DENSITY; BONE MASS; BONE MATURATION; CARDIOMYOPATHY; CHELATION THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COLLAGEN SYNTHESIS; CONSENSUS; CREATININE BLOOD LEVEL; DEMETHYLATION; DIET SUPPLEMENTATION; DNA DAMAGE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MONITORING; ECHOCARDIOGRAPHY; ELECTROPHORESIS; ERYTHROCYTE TRANSFUSION; EVENT FREE SURVIVAL; EYE DISEASE; FEMALE INFERTILITY; FERRITIN BLOOD LEVEL; FOLLOW UP; FRONTAL BOSSING; GASTROINTESTINAL SYMPTOM; GENOTYPE; GRAFT VERSUS HOST REACTION; GROWTH RETARDATION; HEARING DISORDER; HEART OUTPUT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOBILIARY DISEASE; HEPATOMEGALY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERSPLENISM; HYPOGONADISM; HYPOTHALAMUS; IMPAIRED GLUCOSE TOLERANCE; INTESTINE ABSORPTION; IRON ABSORPTION; IRON BLOOD LEVEL; IRON CHELATION; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; KIDNEY FAILURE; LIFE EXPECTANCY; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LUNG VASCULAR RESISTANCE; MAGNETIC FIELD; MEAN CORPUSCULAR VOLUME; MEDLINE; MONOTHERAPY; MYELOABLATIVE CONDITIONING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOBLAST; OSTEOPOROSIS; OVERALL SURVIVAL; OXIDATIVE STRESS; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; PHENOTYPE; PHYSICIAN; PRACTICE GUIDELINE; PSYCHOSOCIAL CARE; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS SYNDROME; RETICULOCYTE COUNT; REVIEW; SIDE EFFECT; SOCIAL BEHAVIOR; SPLENECTOMY; SPLENOMEGALY; STEM CELL TRANSPLANTATION; SUN EXPOSURE; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; UMBILICAL CORD; UMBILICAL CORD BLOOD; VITAMIN SUPPLEMENTATION; ZINC BLOOD LEVEL;

ARABIA; BETA-THALASSEMIA; CONSENSUS; HUMANS;

EID: 84883850016     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-143     Document Type: Review

References (118)

1. Thalassaemia. Higgs DR, Engel JD, Stamatoyannopoulos G, Lancet 2012 379 373 383 10.1016/S0140-6736(11)60283-3 21908035
2. Iron chelation therapy in the management of thalassemia: the Asian perspectives. Viprakasit V, Lee-Lee C, Chong QT, Lin KH, Khuhapinant A, Int J Hematol 2009 90 435 445 10.1007/s12185-009-0432-0 19862602
3. Spectrum of alpha-thalassemia mutations in transfusion-dependent beta-thalassemia patients from the Eastern Province of Saudi Arabia. Akhtar MS, Qaw F, Borgio JF, Albuali W, Suliman A, Nasserullah Z, Al-Jarrash S, Al-Ali A, Hemoglobin 2013 37 65 73 10.3109/03630269.2012.753510 23297837
4. Thalassemia http://www.cdc.gov/ncbddd/blooddisorders/documents/BBV-PNV- C0-1159-Thalassemia-R2mtr.pdf
5. Pathophysiology and Clinical Manifestations of the beta-Thalassemias. Nienhuis AW, Nathan DG, Cold Spring Harb Perspect Med 2012 2 011726 10.1101/cshperspect.a011726 23209183
6. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D, Blood 2006 107 3455 3462 10.1182/blood-2005-08-3430 16352812
7. Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major. Wood JC, Claster S, Carson S, Menteer JD, Hofstra T, Khanna R, Coates T, Br J Haematol 2008 141 891 894 10.1111/j.1365-2141.2008.07135.x 18371108 (Pubitemid 351724869)
8. Alpha and beta thalassemia. Muncie HL Jr, Campbell J, Am Fam Physician 2009 80 339 344 19678601
9. Molecular therapies in beta-thalassaemia. Quek L, Thein SL, Br J Haematol 2007 136 353 365 10.1111/j.1365-2141.2006.06408.x 17129232 (Pubitemid 46046294)
10. Multicenter study of the molecular basis of thalassemia intermedia in different ethnic populations. Verma IC, Kleanthous M, Saxena R, Fucharoen S, Winichagoon P, Raizuddin S, Khan SN, Akbari MT, Izadyar M, Kotea N, Old JM, Ioannou PA, Khan B, Hemoglobin 2007 31 439 452 10.1080/03630260701641245 17994378 (Pubitemid 350125634)
11. Detection of Hemoglobinopathies in Hypochromic, Microcytic and Sickeled Cell Blood Films by Hemoglobin Electrophoresis. Alamiry AAN, Ali TH, Majeed MN, Thi-Qar Med J 2011 5 139 148
12. Prevalence of β-thalassemia trait in premarital screening in Al-Hassa, Saudi Arabia. Al-Sulaiman A, Ann Saudi Med 2006 26 14 16 16521869
13. Incidence of Genetic Disorders of Hemoglobins in the Hospital Population of Bahrain. Nadkarni KV, Al-Arrayed SS, Bapat JP, Bahrain Med Bull 1991 13
14. Distribution of Hemoglobinopathies and Thalassemias in Qatari Nationals Seen at Hamad Hospital in Qatar. Fawzi ZO, Al Hilali A, Fakhroo N, Al Bin Ali A, Al Mansour S, Qatar Med J 2003 12
15. Red cell genetic abnormalities in Peninsular Arabs: sickle haemoglobin, G6PD deficiency, and alpha and beta thalassaemia. White JM, Byrne M, Richards R, Buchanan T, Katsoulis E, Weerasingh K, J Med Genet 1986 23 245 251 10.1136/jmg.23.3.245 3723553 (Pubitemid 16077086)
16. Study of hemoglobinopathies in Oman through a national register. Rajab AG, Patton MA, Modell B, Saudi Med J 2000 21 1168 1172 11360093
17. Genetic Blood Disorders Survey in the Sultanate of Oman. Al-Riyami A, Ebrahim GJ, J Trop Pediatr 2003 49 Suppl 1 1 20 12934793
18. Spectrum of beta-thalassemia mutations in the eastern province of Saudi Arabia. Al-Sultan A, Phanasgaonkar S, Suliman A, Al-Baqushi M, Nasrullah Z, Al-Ali A, Hemoglobin 2011 35 125 134 10.3109/03630269.2011.553567 21417569
19. Sickle beta 0 thalassemia in Eastern Saudi Arabia. Pembrey ME, Perrine RP, Wood WG, Weatherall DJ, Am J Hum Genet 1980 32 26 41 6153864 (Pubitemid 10154991)
20. The population genetics of the haemoglobinopathies. Flint J, Harding RM, Boyce AJ, Clegg JB, Baillieres Clin Haematol 1998 11 1 51 10.1016/S0950-3536(98) 80069-3 10872472 (Pubitemid 29039017)
21. The Spectrum of beta-Thalassemia Mutations in the Arab Populations. Zahed L, J Biomed Biotechnol 2001 1 129 132 10.1155/S1110724301000298 12488606 (Pubitemid 46842819)
22. The frequency of 14 beta-thalassemia mutations in the Arab populations. El-Hazmi MA, Warsy AS, Al-Swailem AR, Hemoglobin 1995 19 353 360 10.3109/03630269509005827 8718694 (Pubitemid 3008601)
23. Molecular heterogeneity of beta-thalassemia in the United Arab Emirates. Baysal E, Community Genet 2005 8 35 39 10.1159/000083336 15767753 (Pubitemid 40529175)
24. Thalassemia. Aydinok Y, Hematology 2012 17 Suppl 1 28 31 22507773
25. Spleen size in beta-thalassaemia heterozygotes. Tassiopoulos T, Rombos Y, Konstantopoulos K, Revenas K, Tassiopoulos S, Aessopos A, Haematologia (Budap) 1995 26 205 209
26. Prevalence of hepatosplenomegaly in beta thalassemia minor subjects in Iran. Karimi M, Bagheri MH, Tahmtan M, Shakibafard A, Rashid M, Eur J Radiol 2009 69 120 122 10.1016/j.ejrad.2007.09.027 18029131
27. The beta-thalassemias. Olivieri NF, N Engl J Med 1999 341 99 109 10.1056/NEJM199907083410207 10395635 (Pubitemid 29314242)
28. Cardiac involvement in thalassemia intermedia: a multicenter study. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, Joussef J, Rombos J, Loukopoulos D, Blood 2001 97 3411 3416 10.1182/blood.V97. 11.3411 11369631
29. Age-related complications in treatment-naive patients with thalassaemia intermedia. Taher AT, Musallam KM, El-Beshlawy A, Karimi M, Daar S, Belhoul K, Saned MS, Graziadei G, Cappellini MD, Br J Haematol 2010 150 486 489 20456362
30. Thalassemia Syndromes. Forget B, Hematology: Basic Principles and Practice New York: Churchill Livingstone, Hoffman R, Benz EJ, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P, 3 2000
31. Beta-thalassemia. Galanello R, Origa R, Orphanet J Rare Dis 2010 5 11 10.1186/1750-1172-5-11 20492708
32. Beta-thalassemia. Cao A, Galanello R, Genet Med 2010 12 61 76 10.1097/GIM.0b013e3181cd68ed 20098328
33. Insight onto the pathophysiology and clinical complications of thalassemia intermedia. Cappellini MD, Musallam KM, Taher AT, Hemoglobin 2009 33 Suppl 1 145 159 20001620
34. Haematological and clinical features of beta-thalassaemia associated with Hb Dhofar. Daar S, Gravell D, Hussein HM, Pathare AV, Wali Y, Krishnamoorthy R, Eur J Haematol 2008 80 67 70 18173741 (Pubitemid 350265234)
35. T2* MRI in regularly transfused children with thalassemia intermedia: serum ferritin does not reflect liver iron stores. Tony S, Daar S, Elshinawy M, Al-Zadjaly S, Al-Khabori M, Wali Y, Pediatr Hematol Oncol 2012 29 579 584 10.3109/08880018.2012.708891 22839111
36. Bunn H, Forget B, Hemoglobin: Molecular, Genetic and Clinical Aspects Philadelphia: W B Saunders Co. 1986
37. The Thalessemias. Weatherall D, Molecular Basis of Blood Diseases Philadelphia: W B Saunders Co, Stamatoyannopoulos G, Nienhuis A, Majerus P, 2 1994
38. Structural hemoglobin variants that produce the phenotype of thalassemia. Adams JG 3rd, Coleman MB, Semin Hematol 1990 27 229 238 2197726 (Pubitemid 20209690)
39. Hemoglobin Synthesis and the Thalassemias. Forget B, Pearson H, Blood: Principles and Practice of Hematology Philadelphia: JB Lippincott, Handin R, Lux S, Stoesel T, 1995
40. Thalassemia Syndromes. Schwartz E, Benx E Jr, Smith's Blood Diseases of Infancy and Childhood St Louis: CV Mosby, Miller D, Baehner R, 6 1989 428 24052943
41. Infections and thalassaemia. Vento S, Cainelli F, Cesario F, Lancet Infect Dis 2006 6 226 233 10.1016/S1473-3099(06)70437-6 16554247
42. Severe infections in thalassaemic patients: prevalence and predisposing factors. Rahav G, Volach V, Shapiro M, Rund D, Rachmilewitz EA, Goldfarb A, Br J Haematol 2006 133 667 674 10.1111/j.1365-2141.2006.06082.x 16704445 (Pubitemid 43742785)
43. The morbidity of bone disease in thalassemia. Vichinsky EP, Ann N Y Acad Sci 1998 850 344 348 10.1111/j.1749-6632.1998.tb10491.x 9668556 (Pubitemid 28369775)
44. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D, Br J Haematol 2003 123 730 737 10.1046/j.1365-2141. 2003.04657.x 14616979 (Pubitemid 37468072)
45. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G, Br J Haematol 2006 134 438 444 10.1111/j.1365-2141.2006.06203.x 16822284 (Pubitemid 44079558)
46. Cunningham M, Sankaran V, Nathan D, Orkin S, The Thalassemias. In Nathan And Oski's Hematology Of Infancy And Childhood. 7th edition Philadelphia: Saunders Elsevier 2009
47. The administration of blood and blood components and the management of transfused patients. British Committee for Standards in Haematology, Blood Transfusion Task Force. Royal College of Nursing and the Royal College of Surgeons of England. British Committee for Standards in Haematology Blood Transfusion Task Force, Transfus Med 1999 9 227 238 10.1046/j.1365-3148.1999. 00203.x 10555817 (Pubitemid 29452158)
48. Transfusion-related acute lung injury (TRALI): current clinical and pathophysiologic considerations. Swanson K, Dwyre DM, Krochmal J, Raife TJ, Lung 2006 184 177 185 10.1007/s00408-005-2578-8 16902843 (Pubitemid 44222466)
49. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Cazzola M, De Stefano P, Ponchio L, Locatelli F, Beguin Y, Dessi C, Barella S, Cao A, Galanello R, Br J Haematol 1995 89 473 478 10.1111/j.1365-2141.1995.tb08351.x 7734344
50. Consensus statement on red cell transfusion. Royal College of Physicians of Edinburgh, Transfus Med 1994 4 177 178 7827643
51. Transfusion medicine. First of two parts-blood transfusion. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP, N Engl J Med 1999 340 438 447 10.1056/NEJM199902113400606 9971869 (Pubitemid 29084776)
52. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A, Haematologica 2004 89 1187 1193 15477202 (Pubitemid 39390442)
53. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Modell B, Khan M, Darlison M, Lancet 2000 355 2051 2052 10.1016/S0140-6736(00)02357-6 10885361 (Pubitemid 30339248)
54. Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review. Evangeli M, Mughal K, Porter JB, Hemoglobin 2010 34 305 321 10.3109/03630269.2010.485080 20524820
55. Disorders of iron metabolism. Andrews NC, N Engl J Med 1999 341 1986 1995 10.1056/NEJM199912233412607 10607817 (Pubitemid 30010408)
56. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, Liu Y, Amariglio N, Rechavi G, Rachmilewitz EA, Breuer W, Cabantchik ZI, Wrighting DM, Andrews NC, de Sousa M, Giardina PJ, Grady RW, Rivella S, Blood 2007 109 5027 5035 10.1182/blood-2006-09-048868 17299088 (Pubitemid 46827803)
57. Body iron metabolism and pathophysiology of iron overload. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J, Int J Hematol 2008 88 7 15 10.1007/s12185-008-0120-5 18594779
58. Iron-chelating therapy and the treatment of thalassemia. Olivieri NF, Brittenham GM, Blood 1997 89 739 761 9028304 (Pubitemid 27121266)
59. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, Gordon SC, Galan MV, Tung BY, Ioannou GN, Kowdley KV, Ann Intern Med 2003 138 627 633 10.7326/0003-4819-138-8-200304150- 00008 12693884
60. Hepatic iron concentration and total body iron stores in thalassemia major. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G, N Engl J Med 2000 343 327 331 10.1056/NEJM200008033430503 10922422 (Pubitemid 30616698)
61. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R, Blood 2005 105 855 861 10.1182/blood-2004-01-0177 15256427 (Pubitemid 40070775)
62. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ, Eur Heart J 2001 22 2171 2179 10.1053/euhj.2001.2822 11913479 (Pubitemid 33139463)
63. Frequency of Agranulocytosis and Mild Neutropenia During Deferiprone Therapy in Clinical Practice. Elalfy M, Shebl S, Badr M, Elsafy U, Salama M, Al-Tonbary Y, Abdel Rahman Y, Qari M, Al Damnhouri G, Al Hawsawi Z, Wali Y, Yesilipek M, Kilinc Y, Yazman D, Karakas Z, Tricta F, ASH Annual Meeting 2012 120 996
64. What is new in iron overload? Vermylen C, Eur J Pediatr 2008 167 377 381 10.1007/s00431-007-0604-y 17899187 (Pubitemid 351322481)
65. Iron-chelation therapy with oral chelators in patients with thalassemia major. Uygun V, Kurtoglu E, Hematology 2013 18 50 55 10.1179/1607845412Y. 0000000046 23321010
66. Bone marrow transplantation in patients with thalassemia. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, Politi P, Durazzi SM, Muretto P, Albertini F, N Engl J Med 1990 322 417 421 10.1056/ NEJM199002153220701 2300104 (Pubitemid 20059509)
67. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, Andreani M, Agostinelli F, Albertini F, Clift RA, N Engl J Med 1993 329 840 844 10.1056/NEJM199309163291204 8355742 (Pubitemid 23267211)
68. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Sodani P, Gaziev D, Polchi P, Erer B, Giardini C, Angelucci E, Baronciani D, Andreani M, Manna M, Nesci S, Lucarelli B, Clift RA, Lucarelli G, Blood 2004 104 1201 1203 10.1182/blood-2003-08-2800 15039283 (Pubitemid 39038044)
69. Allogeneic stem cell transplantation in patients with beta-thalassemia: King Faisal Specialist Hospital and Research Centre Experience. Al-Jefri A, Ayas A, Al Musa A, Al Mahr M, Al Saleh M, Rifai S, Sabbah R, Al Seraihy A, Al Ahmari A, Khairy E, Al Hassan I, El Solh H, Hemoglobin 2009 33 Suppl 1 183 187 20001624
70. Hematopoietic stem cell transplantation for hemoglobinopathies: current practice and emerging trends. Smiers FJ, Krishnamurti L, Lucarelli G, Pediatr Clin North Am 2010 57 181 205 10.1016/j.pcl.2010.01.003 20307718
71. Advances in allogeneic stem cell transplantation for hemoglobinopathies. Al Jefri AH, Hemoglobin 2011 35 469 475 10.3109/03630269.2011.618567 21967642
72. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Gaziev J, Sodani P, Lucarelli G, Polchi P, Marktel S, Paciaroni K, Marziali M, Isgro A, Simone MD, Roveda A, Montuoro A, Lanti A, Alfieri C, De Angelis G, Gallucci C, Ciceri F, Roncarolo MG, Bone Marrow Transplant 2008 42 397 404 10.1038/bmt.2008.175 18574445
73. Advances in the allogeneic transplantation for thalassemia. Lucarelli G, Gaziev J, Blood Rev 2008 22 53 63 10.1016/j.blre.2007.10.001 18039551 (Pubitemid 351282443)
74. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Bernardo ME, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A, Pagliara D, Contoli B, Pinto RM, Caocci G, Mastronuzzi A, La Nasa G, Locatelli F, Blood 2012 120 473 476 10.1182/blood-2012-04-423822 22645178
75. A novel conditioning regimen improves outcomes in beta-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Li C, Wu X, Feng X, He Y, Liu H, Pei F, Liao J, He L, Shi L, Li N, Liu Q, Liu S, Chen G, Su Q, Ren Y, Wang Y, Tan W, Blood 2012 120 3875 3881 10.1182/blood-2012-03- 417998 22968457
76. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Locatelli F, Rocha V, Reed W, Bernaudin F, Ertem M, Grafakos S, Brichard B, Li X, Nagler A, Giorgiani G, Haut PR, Brochstein JA, Nugent DJ, Blatt J, Woodard P, Kurtzberg J, Rubin CM, Miniero R, Lutz P, Raja T, Roberts I, Will AM, Yaniv I, Vermylen C, Tannoia N, Garnier F, Ionescu I, Walters MC, Lubin BH, Gluckman E, Blood 2003 101 2137 2143 10.1182/blood-2002- 07-2090 12424197 (Pubitemid 36302049)
77. Umbilical Cord Blood Banking and Transplantation: A short review. Alkindi S, Dennison D, Sultan Qaboos Univ Med J 2011 11 455 461 22087393
78. Treatment of iron overload in thalassemia. Cianciulli P, Pediatr Endocrinol Rev 2008 6 Suppl 1 208 213 19337180
79. Growth and puberty and its management in thalassaemia. De Sanctis V, Horm Res 2002 58 Suppl 1 72 79 12373018 (Pubitemid 35316841)
80. Growth, puberty and endocrine function in beta-thalassaemia major. Low LC, J Pediatr Endocrinol Metab 1997 10 175 184 9364350 (Pubitemid 27223664)
81. Bone disease in beta-thalassaemia major. Wonke B, Br J Haematol 1998 103 897 901 10.1046/j.1365-2141.1998.01107.x 9886298 (Pubitemid 29012622)
82. Overview of endocrinopathies associated with beta-thalassaemia major. Perera NJ, Lau NS, Mathews S, Waite C, Ho PJ, Caterson ID, Intern Med J 2010 40 689 696 10.1111/j.1445-5994.2010.02254.x 20492011
83. Growth and puberty in thalassemia major. Raiola G, Galati MC, De Sanctis V, Caruso Nicoletti M, Pintor C, De Simone M, Arcuri VM, Anastasi S, J Pediatr Endocrinol Metab 2003 16 Suppl 2 259 266 12729401 (Pubitemid 37259059)
84. Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment. Chatterjee R, Bajoria R, Hemoglobin 2009 33 Suppl 1 136 138 20001617
85. Growth hormone and adrenal response to intramuscular glucagon test and its relationship to IGF-1 production and left ventricular ejection fraction in adult B-thalassemia major patients. De Sanctis V, Skordis N, Galati MC, Raiola G, Giovannini M, Candini G, Kaffe K, Savvides I, Christou S, Pediatr Endocrinol Rev 2011 8 Suppl 2 290 294 21705980
86. Hypogonadotrophic hypogonadism and diminished gonadal reserve accounts for dysfunctional gametogenesis in thalassaemia patients with iron overload presenting with infertility. Bajoria R, Chatterjee R, Hemoglobin 2011 35 636 642 10.3109/03630269.2011.623809 22035015
87. Evaluation of growth, puberty and endocrine dysfunctions in relation to iron overload in multi transfused Indian thalassemia patients. Merchant RH, Shirodkar A, Ahmed J, Indian J Pediatr 2011 78 679 683 10.1007/s12098-010-0351-3 21234716
88. Sex steroid priming for induction of puberty in thalassemia patients with pulsatile reversible hypogonadotrophic hypogonadism. Chatterjee R, Mukhopadhyay TN, Chandra S, Bajoria R, Hemoglobin 2011 35 659 664 10.3109/03630269.2011. 630121 22074126
89. The hypercoagulable state in thalassemia. Eldor A, Rachmilewitz EA, Blood 2002 99 36 43 10.1182/blood.V99.1.36 11756150 (Pubitemid 34532962)
90. Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection. Barnett CF, Hsue PY, Machado RF, JAMA 2008 299 324 331 10.1001/jama.299.3.324 18212317 (Pubitemid 351159369)
91. Radiofrequency ablation of the spleen in patients with thalassemia intermedia: a pilot study. Rasekhi AR, Naderifar M, Bagheri MH, Shahriari M, Foroutan H, Karimi M, Nabavizadeh SA, Am J Roentgenol 2009 192 1425 1429 10.2214/AJR.08.1382
92. Splenectomy for haematological disorders: a single center study in 150 patients from Oman. Machado NO, Grant CS, Alkindi S, Daar S, Al-Kindy N, Al Lamki Z, Ganguly SS, Int J Surg 2009 7 476 481 10.1016/j.ijsu.2009.08.004 19695352
93. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists Number 64, July 2005 (Replaces Committee Opinion Number 238, July 2000): hemoglobinpathies in pregnancy. ACOG Committee, Obstetrics and Gynecology 2005 106 203 210 10.1097/00006250-200507000-00052 15994657
94. Society for the Study of T, Hemoglobinopathies: Guideline recommendations for heart complications in thalassemia major. Cogliandro T, Derchi G, Mancuso L, Mayer MC, Pannone B, Pepe A, Pili M, Bina P, Cianciulli P, De Sanctis V, Maggio A, J Cardiovasc Med (Hagerstown) 2008 9 515 525 10.2459/JCM. 0b013e3282f20847 (Pubitemid 351521635)
95. Pregnancy and beta-thalassemia: an Italian multicenter experience. Origa R, Piga A, Quarta G, Forni GL, Longo F, Melpignano A, Galanello R, Haematologica 2010 95 376 381 10.3324/haematol.2009.012393 19903676
96. Exjade product monograph USA 2011 http://www.drugs.com/monograph/exjade. html
97. Ferriprox product monograph http://www.drugs.com/monograph/deferiprone. html
98. Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years. Deugnier Y, Turlin B, Ropert M, Cappellini MD, Porter JB, Giannone V, Zhang Y, Griffel L, Brissot P, Gastroenterology 2011 141 1201 1203 1202-1211, 1211
99. Iron Balance in β-thalassemia: Maintaining an Oxidant/Antioxidant Ratio. Patel H, Qari M, Mousa S, J App Hematol 2012 3 4 11
100. Cappellini M-D, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A, Guidelines for the clinical management of thalassemia Nicosia, Cyprus: Thalassemia International Federation 2 2008
101. Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapradang A, Domrongkitchaiporn S, Sirisriro R, Rajatanavin R, J Clin Endocrinol Metab 2003 88 3966 3972 10.1210/jc.2002-021548 12915694 (Pubitemid 37034553)
102. Bone loss caused by iron overload in a murine model: importance of oxidative stress. Tsay J, Yang Z, Ross FP, Cunningham-Rundles S, Lin H, Coleman R, Mayer-Kuckuk P, Doty SB, Grady RW, Giardina PJ, Boskey AL, Vogiatzi MG, Blood 2010 116 2582 2589 10.1182/blood-2009-12-260083 20554970
103. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N, Osteoporos Int 2001 12 570 575 10.1007/s001980170079 11527055 (Pubitemid 32777434)
104. Cardiovascular aspect of Beta-thalassaemia. Taksande A, Prabhu S, Venkatesh S, Cardiovasc Hematol Agents Med Chem 2012 10 25 30 10.2174/187152512799201172 22239492
105. Thromboembolic events in beta thalassemia major: an Italian multicenter study. Borgna Pignatti C, Carnelli V, Caruso V, Dore F, De Mattia D, Di Palma A, Di Gregorio F, Romeo MA, Longhi R, Mangiagli A, Melevendi C, Pizzarelli G, Musumeci S, Acta Haematol 1998 99 76 79 10.1159/000040814 9554453 (Pubitemid 28119099)
106. Guideline recommendations for heart complications in thalassemia major. Cogliandro T, Derchi G, Mancuso L, Mayer MC, Pannone B, Pepe A, Pili M, Bina P, Cianciulli P, De Sanctis V, Maggio A, J Cardiovasc Med (Hagerstown) 2008 9 515 525 10.2459/JCM.0b013e3282f20847 (Pubitemid 351521635)
107. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, Fucharoen S, Cianciulli P, Grady RW, Prossomariti L, Porter JB, Iacono A, Cappellini MD, Bonifazi F, Cassara F, Harmatz P, Wood J, Gluud C, Blood Cells Mol Dis 2011 47 166 175 10.1016/j.bcmd.2011.07.002 21843958
108. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ, J Cardiovasc Magn Reson 2008 10 42 10.1186/1532-429X-10-42 18817553
109. Restrictive pulmonary dysfunction and its predictors in young patients with beta-thalassaemia major. Bourli E, Dimitriadou M, Economou M, Vlachaki E, Christoforidis A, Maratou E, Stanopoulos I, Argyropoulou P, Aivazis V, Pediatr Pulmonol 2012 47 801 807 10.1002/ppul.22506 22328228
110. Pulmonary hypertension in thalassemia. Morris CR, Vichinsky EP, Ann N Y Acad Sci 2010 1202 205 213 10.1111/j.1749-6632.2010.05580.x 20712794
111. Clinical indicators for pulmonary arterial hypertension in thalassemia. Chueamuangphan N, Wongtheptien W, Nawarawong W, Sukornthasarn A, Chuncharunee S, Tawichasri C, Patumanond J, J Med Assoc Thai 2012 95 16 21 22379736
112. Psychosocial implications of Thalassemia Major. Aydinok Y, Erermis S, Bukusoglu N, Yilmaz D, Solak U, Pediatr Int 2005 47 84 89 10.1111/j.1442-200x. 2004.02009.x 15693873 (Pubitemid 40314617)
113. Psychosocial aspects and psychiatric disorders in children with thalassemia major. Aydin B, Yaprak I, Akarsu D, Okten N, Ulgen M, Acta Paediatr Jpn 1997 39 354 357 10.1111/j.1442-200X.1997.tb03752.x 9241900 (Pubitemid 27276378)
114. Quality of life in patients with thalassemia intermedia compared to thalassemia major. Pakbaz Z, Treadwell M, Yamashita R, Quirolo K, Foote D, Quill L, Singer T, Vichinsky EP, Ann N Y Acad Sci 2005 1054 457 461 10.1196/annals.1345.059 16339697 (Pubitemid 43031056)
115. Guideline, Alternative approaches to the treatment of thalassemia http://www.ithanet.eu/ithapedia/index.php/Guideline:Alternative-approaches-to- the-treatment-of-thalassemia
116. Prediction, validation and targeted interference of erythroid regulatory modules. Wang H, Dissertation University Park, PA, USA: The Pennsylvania State University, Eberly College of Science 2006
117. Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Alhamdan NA, Almazrou YY, Alswaidi FM, Choudhry AJ, Genet Med 2007 9 372 377 10.1097/GIM.0b013e318065a9e8 17575503 (Pubitemid 46956479)
118. Preimplantation diagnosis of thalassemias. Kuliev A, Rechitsky S, Verlinsky O, Ivakhnenko V, Evsikov S, Wolf G, Angastiniotis M, Georghiou D, Kukharenko V, Strom C, Verlinsky Y, J Assist Reprod Genet 1998 15 219 225 10.1023/A:1022571822585 9604751 (Pubitemid 28223979)